These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 16302640)

  • 21. Treatment of uncomplicated urinary tract infections in an era of increasing antimicrobial resistance.
    Miller LG; Tang AW
    Mayo Clin Proc; 2004 Aug; 79(8):1048-53; quiz 1053-4. PubMed ID: 15301333
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Increasing antimicrobial resistance and the management of uncomplicated community-acquired urinary tract infections.
    Gupta K; Hooton TM; Stamm WE
    Ann Intern Med; 2001 Jul; 135(1):41-50. PubMed ID: 11434731
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [A case of urinary tract infection caused by Flavimonas oryzihabitans].
    Topkaya AE; Ozakkaş F; Aksungar FB; Tülbek Y
    Mikrobiyol Bul; 2007 Jan; 41(1):133-7. PubMed ID: 17427563
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A comparison of antimicrobial susceptibility profile of urinary pathogens for the years, 1999 and 2003.
    Orrett FA; Davis GK
    West Indian Med J; 2006 Mar; 55(2):95-9. PubMed ID: 16921702
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Therapeutic effect of the quinolone prodrug prulifloxacin against experimental urinary tract infections in mice.
    Tomii Y; Ozaki M; Matsuda M; Honmura T; Nishimura I; Yamaguchi R; Adachi T; Okawa Y; Nishino T
    Arzneimittelforschung; 1996 Dec; 46(12):1169-73. PubMed ID: 9006794
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Bacteriological analysis of more than 600 febrile urinary infections managed in a community health network].
    Bruyère F; Vidoni M; Péan Y; Ruimy JA; Elfassi R
    Prog Urol; 2013 Sep; 23(10):890-8. PubMed ID: 24034802
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Resistance to fluoroquinolones and treatment failure/short-term relapse of community-acquired urinary tract infections caused by Escherichia coli.
    Gagliotti C; Buttazzi R; Sforza S; Moro ML;
    J Infect; 2008 Sep; 57(3):179-84. PubMed ID: 18707763
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Evaluation of levofloxacin susceptibility against strains isolated from lower urinary tract infections in the community].
    Weber P; Dib C; Durand C; Moniot-Ville N
    Pathol Biol (Paris); 2005 Mar; 53(2):125-8. PubMed ID: 15708658
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Ten years surveillance of antimicrobial susceptibility of community-acquired Escherichia coli and other uropathogens in northern Israel (1995-2005).
    Rock W; Colodner R; Chazan B; Elias M; Raz R
    Isr Med Assoc J; 2007 Nov; 9(11):803-5. PubMed ID: 18085038
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Role of levofloxacin in the treatment of urinary tract infections].
    Trinchiere A
    Arch Ital Urol Androl; 2001 Jun; 73(2):105-13. PubMed ID: 11758533
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Ofloxacin. A reappraisal of its use in the management of genitourinary tract infections.
    Onrust SV; Lamb HM; Balfour JA
    Drugs; 1998 Nov; 56(5):895-928. PubMed ID: 9829160
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Antibiotic susceptibility and arsenic tolerance of urinary bacteria isolated from arsenic-exposed people in Nepal.
    Maden N; Singh A; Smith LS
    Microb Drug Resist; 2011 Mar; 17(1):53-8. PubMed ID: 21128838
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prulifloxacin: a new antibacterial fluoroquinolone.
    Prats G; Rossi V; Salvatori E; Mirelis B
    Expert Rev Anti Infect Ther; 2006 Feb; 4(1):27-41. PubMed ID: 16441207
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Ofloxacin: new applications for the prevention of urinary tract infections in renal graft recipients.
    Rafat C; Vimont S; Ancel PY; Xu-Dubois YC; Mesnard L; Ouali N; Denis M; Vandewalle A; Rondeau E; Hertig A
    Transpl Infect Dis; 2011 Aug; 13(4):344-52. PubMed ID: 21299776
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Incidence of antibiotics resistance among uropathogens in Omani children presenting with a single episode of urinary tract infection.
    Sharef SW; El-Naggari M; Al-Nabhani D; Al Sawai A; Al Muharrmi Z; Elnour I
    J Infect Public Health; 2015; 8(5):458-65. PubMed ID: 25755002
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Review of ceftaroline fosamil microbiology: integrated FOCUS studies.
    Critchley IA; Eckburg PB; Jandourek A; Biek D; Friedland HD; Thye DA
    J Antimicrob Chemother; 2011 Apr; 66 Suppl 3():iii45-51. PubMed ID: 21482569
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Levofloxacin in the treatment of urinary tract infections and prostatitis.
    Naber KG
    J Chemother; 2004 Apr; 16 Suppl 2():18-21. PubMed ID: 15255558
    [No Abstract]   [Full Text] [Related]  

  • 38. Antibiotic sensitivity pattern of common community-acquired uropathogens in children in a Saudi tertiary care hospital.
    Al-Saif MA; Al-Abdi SY; Samara JT; Al-Rahman NG; Mousa TA; Alabdulbaqi MA; Yiannakou NG
    Saudi Med J; 2012 May; 33(5):565-7. PubMed ID: 22588821
    [No Abstract]   [Full Text] [Related]  

  • 39. Emerging drugs for bacterial urinary tract infections.
    Wagenlehner FM; Weidner W; Perletti G; Naber KG
    Expert Opin Emerg Drugs; 2010 Sep; 15(3):375-97. PubMed ID: 20569081
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Outcomes of high-dose levofloxacin therapy remain bound to the levofloxacin minimum inhibitory concentration in complicated urinary tract infections.
    Armstrong ES; Mikulca JA; Cloutier DJ; Bliss CA; Steenbergen JN
    BMC Infect Dis; 2016 Nov; 16(1):710. PubMed ID: 27887579
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.